anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a method for manufacturing an intraoral adhesive mounting body, etc., wherein the intraoral adhesive mounting body having high accuracy of being fitted to a mucosa or tooth in a mouth is manufactured with simple and inexpensive equipment, with respect to manufacturing of the intraoral adhesive mounting body using a photopolymerization resin.  <P>SOLUTION: At first, the side of a front surface 2b of the photopolymerization resin 2 abutted on a portion 11 like the shape of an intraoral mucosa in a model 1 is covered with a light shielding body 4. Then, light is radiated from the side of a rear surface 2a of the photopolymerization resin 2 via a translucent glass flat plate 3 and the model 1. Thus, the polymerization hardening of the photopolymerization resin 2 is started from the rear surface 2a of the photopolymerization resin 2. Therefore, the side of the rear surface 2a of the photopolymerization resin 2 is not floated from the portion 11 like the shape of the intraoral mucosa in the model 1, thereby to faithfully reproduce the shape of the intraoral mucosa.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
The physical state of fat has been demonstrated to affect the rate of fat digestion. By engineering the physical properties of lipid emulsions the investigators are able to alter characteristics such as acid stability, lipid droplet size and fat redispersibility. These factors have been shown to modulate the physical state of fat in the stomach, the subsequent fat gastric emptying and digestion as well as satiation in healthy subjects. The investigators have recently developed a new series of lipid emulsions based on biopolymers. Preliminary animal studies have shown that these emulsions are able to effect GI physiology including GI peptide hormones and eating behavior. The primary aim of this work is to apply these biopolymer based lipid emulsions in healthy subjects and investigate their impact on fat digestion and satiation. A secondary aim is to develop an image analysis method that can quantify the heterogeneity of fat distribution within gastric content from the MRI data.

The participants (n=17) will be randomized at screening to receive 3 of the 4 lipid emulsions (LE).

On each of the three study days subjects will receive 200 mL of a lipid emulsion. MRI scans will be performed at regular intervals over a period of 3.5 h. Blood samples (for GI peptide hormone analysis) will also be taken at regular intervals until 5 h post LE ingestion. Further, 13C breath test samples will be obtained from participants every 10 min until 5 h post ingestion of LE. Throughout the entire 5 h study period participants will be asked to score their visceral sensation in relation to satiation. Once the technical section of the study is complete the participant will be provided with an ad libitum buffet from which they can consume as much or a little of the food options provided in the buffet.

Optional study day: After the main study is complete and the MRI data has been analyzed the study will be unblinded. This will enable the investigators to optimize an MR imaging and gastric content sampling schedule for LE5 and LE6. The participants (n=17) will be randomized and 10 subjects will then be given the opportunity to participate in the optional study day. The optional study day is single blinded and consists of 1 extra visit and is of a maximum 3 h duration. No bloods, breath test samples or visceral sensation scores will be taken. Subjects will arrive fasted and a nasogastric tube will be positioned. 200 mL of either LE5 or LE6 containing the 13C breath test marker will then be infused. MR imaging will continue at defined intervals until maximum of 3 h. In total five gastric content samples of 5 mL will be taken with the nasogastric tube.
PURPOSE: An antifungal composition containing polylysine is provided to ensure antifungal activity against Malassezia sp. and to effectively prevent or treat dandruff without side effects. CONSTITUTION: An antifungal composition against Malassezia sp. contains polylysine as an active ingredient. A composition for preventing or treating dandruff contains the antifungal composition as an active ingredient. The cosmetic composition for preventing or treating dandruff contains the antifungal composition as an active ingredient. A cleansing composition for preventing or treating dandruff contains the antifungal composition as an active ingredient.
Heterocyclic compounds are provided. In particular, the heteroatom of the heterocyclic compound may be nitrogen. The heterocyclic compound may exhibit the ability to stabilize the photosensitive compound. Topical compositions comprising these heterocyclic compounds are also provided. In particular, these topical compositions further comprise a photosensitive compound. Methods of stabilizing photosensitive compounds are also provided. These methods include mixing a photosensitive compound with a light stabilizer heterocyclic compound.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent stability at a high temperature near a specific temperature such as bodily temperature and useful for pharmaceuticals, cosmetics, foods, etc., by including a cyclodipeptide derivative. SOLUTION: A compound of the formula (R1 is a 1-4C alkyl, benzyl, etc.; R2 is a 6-22C alkyloxycarbonyl, etc.) is produced by refluxing an alkyl ester of a dipeptide in 1,3,5-trimethylbenzene under heating, hydrogenating the obtained cyclodipeptide alkyl ester with hydrogen using a Pd catalyst and esterifying the product. The objective composition can be produced by using the obtained compound as a component in an amount of 0.1-100 pts.wt., preferably 0.5-90 pts.wt. based on 1 pt.wt. of an oily component.
Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
Cerebral vasospasm (CVS) is an important contributor to delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH), leading to high morbidity and long-term disability. While several microRNAs (miRNAs) have been implicated in vasospasm, the underlying mechanisms for CVS remain poorly understood. Our study aims to identify miRNAs that may contribute to the development of CVS. Whole-blood samples were obtained during or outside of vasospasm from aSAH patients whose maximal vasospasm was moderate or severe. MiRNAs were isolated from serial whole-blood samples, and miRNA sequencing was performed. Differentially expressed miRNAs were identified and the expression levels in patients' samples were verified using real-time qPCR. The biological functions of identified miRNA were evaluated in human brain endothelial cells (HBECs). MiRNA profiling revealed significant upregulation of miR-148b-3p in patients during CVS. We demonstrated that miR-148b-3p directly targeted and decreased the expression of ROCK1, affecting cell proliferation, migration, and invasion of HBECs through the ROCK-LIMK-Cofilin pathway. We propose that the upregulation of miRNA-148b-3p plays a role in the development of CVS by regulating actin cytoskeletal dynamics in HBECs, which is crucial for vascular function. Our study highlights miR-148b-3p as a potential diagnostic marker as well as therapeutic target for CVS following aSAH.
The Diabetes Prevention Program (DPP) has been successful in reducing the incidence of type 2 diabetes mellitus (T2DM) through moderate weight loss and increased physical activity, and evidence from the original DPP suggests that adoption of increased physical activity (PA) habits are maintained up to 10 years among intervention participants when compared to control. Hispanic males are difficult to engage in traditional lifestyle or non-communicable chronic disease (NCDs) prevention interventions, yet, they have high rates of obesity and are at high risk for NCDs, particularly T2DM. Small-sided recreational soccer (RS) 6-12 month interventions have shown to be effective to achieve 5% weight loss and reduce cardio-metabolic risk, stemming from its varied movement patterns and highly functional training. Although proven cost-effectiveness and currently expanding in Europe, RS cardio-metabolic preventive interventions have not been tested in U.S. populations.

To fill this gap in health promotion, the goal for this proposal is to utilize the local Hispanic community's interest in soccer as a vehicle to deliver an adapted DPP among male, overweight, Latino adults at high T2DM risk. The researchers will test the following central hypothesis: A soccer-based adaptation to the DPP, can be feasibly implemented in a middle-age Latino men population at high risk for T2DM. In lieu of the traditional walking or exercise program, participants will be enrolled in 12 weeks of soccer conditioning followed by 12 weeks of small-sided soccer league play. National Diabetes Prevention Program (NDPP) online core and maintenance modules will also be facilitated by trained coaches during soccer practice for the first 12 weeks and through monthly in-person meetings the last 12 weeks. Physical activity volume, sleep and sedentary time will be tracked objectively with wearable devices linked to an innovative research smartphone app that provides data to the researchers and tailored in-app notifications and surveys to the participant. Additionally, the study will assess implementation feasibility and explore preliminary signals for improvements in objectively-measured PA, dietary behaviors, physical fitness and body composition and quality of life outcomes with the soccer-based DPP adaptation.
Many people across the spectrum of chronic kidney disease (CKD) experience a large symptom burden. Measuring symptoms can be a way of responding to the concerns of patients and their priorities of care and may help to improve overall outcomes, including health-related quality of life. The objective of this article is to discuss approaches to measuring symptoms across the spectrum of CKD and to highlight strategies to facilitate the incorporation of routine symptom assessment into kidney care. Specifically, we discuss the use of validated patient-reported outcome measures in CKD as they relate to measuring symptoms, including their benefits and limitations, and describe commonly used patient-reported outcome measures. We discuss potential barriers that should be considered when contemplating the development of a program to routinely measure and address symptoms. Finally, we outline a systematic, stepwise approach to measuring symptoms with implementation strategies to address the common barriers. Although the principles outlined in this article can be applied to research and audit, the principal focus is on symptom measurement aimed at informing clinical practice and directly improving patient outcomes.
Connexin proteins are the building blocks of gap junctions and connexin hemichannels. Both provide a pathway for cellular communication. Gap junctions support intercellular communication mechanisms and regulate homeostasis. In contrast, open connexin hemichannels connect the intracellular compartment and the extracellular environment, and their activation fuels inflammation and cell death. The development of clinically applicable connexin hemichannel blockers for therapeutic purposes is therefore gaining momentum. This chapter describes a well-established protocol optimized for assessing connexin hemichannel activity by using the reporter dye Yo-Pro1.
Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
BACKGROUND: The purpose of this research was to evaluate the efficacy of Narcotrend (NT) monitoring on cognitive dysfunction in patients undergoing anesthesia blockade for gastrointestinal tumors and its effect on cerebral oxygen metabolism and inflammatory response.
METHODS: Patients preparing to undergo resection of gastrointestinal tumor resection were included and randomly divided into a control group (depth of anesthesia assessed by physician experience) and a research group (depth of anesthesia monitored by NT). HR and MAP were monitored at the preoperatively (T0), 12 h postoperative (T1), 24 h postoperative (T2), and 48 h postoperative (T3) stages. MMSE score was recorded to assess changes in cognitive function. Intracerebral oxygenation indicators (CjvO2, CERO2, and rSO2) were assessed by a blood gas analyzer. ELISA assay was conducted to explore the serum inflammatory indexes (CRP, IL-1β, and TNF-α) and neurological function indicators (NSE and MBP).
RESULTS: MAP was higher in the research group than in the control group at T1 and T2 (P < 0.05). MMSE scores at T1, T2, and T3 stages were higher in the research group than in the control (P < 0.05). The incidence of POCD was also lower in the research group compared with the control (P < 0.05). CjvO2, CERO2, and rSO2 were significantly higher (P < 0.05) and were positively correlated with the MMSE scores. Postoperative serum inflammatory indexes were significantly elevated in both groups, but more significantly in the control group (P < 0.05). Both neurological function indicators were usually reduced after surgery, but the reduction was more significant in the research group (P < 0.05).
CONCLUSION: NT monitoring of anesthetic depth has a less physical impact on patients with gastrointestinal tumor anesthetic block, reduces the degree of postoperative POCD, and has significant clinical value.
In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m\^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m\^2 or 40 mg/m\^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m\^2 or 125 mg/m\^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
PURPOSE: A cosmetic base composition containing the complex stabilized by microencapsulation of L-ascorbic acid and Terminalia chebula retz. extract to 2-hydroxypropylated-beta-cyclodextrin(HPBCD) is provided which is stabler and safer than the existing cosmetic base containing L-ascorbic acid and the derivative thereof. CONSTITUTION: A complex containing L-ascorbic acid and Terminalia chebula retz. extract can be manufactured by the following steps: (a) 330.0 g of 2-hydroxypropylated-beta-cyclodextrin is dissolved in 1 liter of distilled water at 20°C to get saturated HPBCD aqueous solution; (b) L-ascorbic acid and Terminalia chebula retz. extract are added and then the mixture is agitated for 12-24 hours; (c) the complex is isolated from the agitating solution and washed with distilled water twice or three times; (d) dried under vacuum condition then crushed into the powder of the complex. The content of HPBCD is 0.01-20 wt.%, desirably 0.1-10 wt.%, based on the total weight of the cosmetic base. The content of L-ascorbic acid in the complex is 0.1-80 wt.%, desirably 1.0-60 wt.%, and the content of Terminalia chebula retz. extract is 0.001-5.0 wt.%, desirably 0.01-3.0 wt.%, based on the weight of the complex.
Cold (including influenza) is an acute upper respiratory inflammation caused by viruses, and has a maximum incidence rate during the climate changing period. According to the temperature of climate and different symptoms of diseases, the cold comprises wind-cold cold and wind-heat cold in the traditional Chinese medicine. The wind-cold cold has following symptoms: sensation of chill, fever, wherein the sensation of chill is severer than fever, nasal obstruction, thin nasal discharge, headache, or coughing, no sweating, no thirst, and ache all over. The proved recipe for treating the wind-clod cold adopts traditional Chinese medicine herbals as the raw materials, oral liquid is obtained through a conventional decocting method. Medicines are applied based on the proved recipe according to the disease principles, has no toxic or side effect, and has prominent curative effects on cold, fever, chilling, headache, no sweat, and ache all over. The proved recipe is repeatedly researched for many years, on the basis of curing of a plurality of patients for decades, the curative effect is observed through clinic, the effective rate reaches 98%, and the cure rate reaches 92%. The proved recipe has a good function of preventing cold, and has a prominent effect on preventing influenza. The proved recipe also can strengthen antivirus immunity function of human bodies, has the advantages of short treatment course, rapid effect, good consolidation property, and user-friendliness, and is the only unique prescription for curing wind-cold cold.
FIELD: radiobiology. SUBSTANCE: method involves administration of medicinal plant species infusions before eating. Plant species involves herbs showing moderate diuretic and sudoritic actions and also herbs showing purgative and promoting to food ingestion actions, and potassium-containing herbs also. Plant species infusions were intaken immediately before aqueous-thermic procedure carrying out realized by bath and/or thermochamber. These procedures were carried out by the definite periodicity. EFFECT: accelerated radionuclides removing, clinical and biophysical positive action on human organism.
The method comprises the following steps:   a. Blood plasma is equilibrated with buffer to a slightly basic pH by passing through a first chromatographic column which is itself equilibrated with this buffer. b. The fraction collected at the outlet of this first column is transferred to a second chromatographic column containing Blue-trisacryl, at the outlet of which a protein fraction is recovered. c. This protein fraction is transferred to a third chromatographic column containing DEAE-Trisacryl in order to recover alpha1-antitrypsin by elution.   Application in the separation and recovery of blood components.
Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening. After a minimum of 2 week washout period, subjects then took placebo for 6 weeks.
Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
The present invention relates to body heat-soluble cosmetics for human skin, which is in a solid state capable of maintaining a constant shape at the temperature lower than body heat, is dissolved by the body heat of skin when coming in contact with the skin, and is formed in a tablet type or is formed in a granule type to be encapsulated in a capsule. According to the present invention, the body heat-soluble cosmetics have a solid state capable of maintaining a constant shape at room temperature in normal times, thereby providing advantages of being conveniently carried and being manufactured as solid cosmetic of various diameters and shapes. The body heat-soluble cosmetics are easily dissolved by body heat of skin when coming in contact with the skin, thereby securing user convenience. Moreover, the body heat-soluble cosmetics integrally solidifies anti-wrinkle and whitening components with skin, lotion, and essence components, thereby integrally forming various functional cosmetics easy to carry. Moreover, the body heat-soluble cosmetics maintain a solid state at room temperature, thereby being tableted to be used one by one as necessary or being formed in small particles capable of being stored in a capsule. According to the present invention, the body heat-soluble cosmetics comprise dextrin fatty acid ester, pullulan, and oil.
This study is a randomized (study drug assigned by chance), multicenter (when more than 1 hospital or medical school team work on a medical research study), active-controlled, parallel group (each group of participants will be treated at the same time), double-blind (neither physician nor participant knows the treatment that the participant receives) study. The duration of the treatment will be 2 days and will be conducted in 4 periods: screening period (from 33 to 2 days before study drug administration to the first surgical incision), surgical period (to 1 day before study drug administration), qualification period (1 day) and double-blind treatment period (1 to 2 days). Participants will be randomly assigned to 2 groups: study drug treatment group (ER) and comparator treatment group (IR). Participants will be administered 2 tablets of ER tramadol HCl (75 milligram \[mg\])/acetaminophen (650 mg) along with 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) along with 2 tablets of placebo matching to ER tramadol HCl/acetaminophen in comparator treatment group respectively at 0, 12, 24 and 36 hours. Participants will also be administered 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl/acetaminophen in comparator treatment group respectively at 6, 18, 30 and 42 hours. Participants will be administered investigational product at 6-hour interval from the time of the first investigational product administration over 48 hours. Efficacy will be assessed using 11-point numeric rating scale (NRS). Participants' safety will be monitored throughout the study.
Retinal ischemia is a significant factor in various vision-threatening diseases, but effective treatments are currently lacking. This study explores the potential of stem cell factor (SCF) in regulating the neurovascular unit as a therapeutic intervention for retinal ischemic diseases. A chronic retinal ischemia model was established in Brown Norway rats using bilateral common carotid artery occlusion (BCCAO). Subsequent SCF treatment resulted in a remarkable recovery of retinal function, as indicated by electroretinogram, light/dark transition test, and optokinetic head tracking test results. Histological examination demonstrated a significant increase in the number of retinal neurons and an overall thickening of the retina. Immunofluorescence confirmed these findings and further demonstrated that SCF treatment regulated retinal remodeling. Notably, SCF treatment ameliorated the disrupted expression of synaptic markers in the control group's BCCAO rats and suppressed the activation of Müller cells and microglia. Retinal whole-mount analysis revealed a significant improvement in the abnormalities in retinal vasculature following SCF treatment. Transcriptome sequencing analysis revealed that SCF-induced transcriptome changes were closely linked to the Wnt7 pathway. Key members of the Wnt7 pathway, exhibited significant upregulation following SCF treatment. These results underscore the protective role of SCF in the neurovascular unit of retinal ischemia rats by modulating the Wnt7 pathway. SCF administration emerges as a promising therapeutic strategy for retinal ischemia-related diseases, offering potential avenues for future clinical interventions.
Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).